Form 4: Pliant Therapeutics Executive Sells Shares to Cover Tax Obligations

A Pliant Therapeutics executive, Lily Cheung, sold 3,740 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Lily Cheung, Chief Human Resource Officer at Pliant Therapeutics, sold 3,740 shares of common stock on January 17, 2025, at an average price of $11.2011 per share.
• The sale was executed to cover withholding tax liabilities associated with the vesting of previously granted restricted stock units.
• The sale was part of a larger group sale by employees to cover tax obligations.
• The price range for the shares sold on behalf of the group of employees was between $11.03 and $11.695.
• Cheung also acquired 1,495 shares through an Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock sale for tax purposes) and does not indicate any significant positive or negative sentiment. The employee stock purchase plan is a positive.

Positives

• The employee stock purchase plan allows employees to acquire shares.

Risks

• Executive sales can sometimes be perceived negatively by the market, although this sale appears to be for tax purposes.

Industry Context

Executive stock sales are a common occurrence, especially when related to tax obligations from vesting equity awards. This is a routine transaction and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use similar mechanisms for employee stock purchase plans and restricted stock unit vesting.
• The price range of the sale is within a normal range for market fluctuations.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but it is not expected to be significant.
• Employees benefit from the employee stock purchase plan.

Key Dates

Keywords

Pliant Therapeutics, stock sale, insider trading, Form 4, executive, tax obligations, restricted stock units, employee stock purchase plan